NASH-RX Clinical Trial Protocol Filed with FDA; First Patient Currently Expected to be Enrolled in Second Quarter 2020 Filed a New Form S-3 Shelf Registration Statement Which Replaces the Company’s Existing Shelf Registration Statement, which Expires on June 1, 2020 NORCROSS, Ga.
The first patient currently expected to be enrolled in the second quarter of 2020 NORCROSS, Ga. , April 30, 2020 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced that it has submitted to the U.S.
NORCROSS, Ga. , April 02, 2020 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins today provided an update on the impact of the COVID-19 pandemic on the Company and its clinical trial activities.
Addition of Pol F. Boudes, M.D. as Chief Medical Officer strengthens executive team for launch of Galectin’s NASH-RX trial for the prevention of esophageal varices in patients with NASH cirrhosis NORCROSS, Ga. , March 16, 2020 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc.
Appointment of industry veteran reflects growing confidence in clinical development program for NASH Cirrhosis NORCROSS, Ga., Feb. 20, 2020 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), a leader in the field of NASH therapeutics, today announced the appointment of Pol F.
NORCROSS, Ga. , Feb. 04, 2020 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that Dr. Harold H. Shlevin , the Company’s President and CEO, will present at the 3 rd Global NASH Congress 2020 at the
NORCROSS, Ga. , Dec. 09, 2019 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that a paper highlighting the results of its NASH-CX Phase 2 clinical trial in NASH cirrhosis have been published in the
Interim analysis after 12-18 months of treatment to reaffirm phase 2 results, select optimal dosage and sizing and seamlessly roll into Phase 3 stage of NASH-RX Study Dr. Harold Shlevin , CEO, Discusses Plan at Annual Meeting of Stockholders NORCROSS, Ga. , Dec.
NORCROSS, Ga. , Nov. 26, 2019 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, announced today that Harold H. Shlevin , Ph.D., president and chief executive officer, will present a corporate update via live webcast
NORCROSS, Ga. , Nov. 18, 2019 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that Eliezer Zomer , Ph.D., Vice President, Discovery Research and Product Development for Galectin Therapeutics , will be
Provides Update on NASH-RX Trial Plan NORCROSS, Ga. , Nov. 12, 2019 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the three months ended
NORCROSS, Ga. , Nov. 11, 2019 (GLOBE NEWSWIRE) -- Today, Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, announced a collaboration agreement with Siemens Healthineers , a global leader in medical technology, in nonalcoholic
Baseline enhanced liver fibrosis (ELF) score taken at the beginning of NASH-CX trial accurately predicted which patients were at higher risk of liver-related outcomes NORCROSS, Ga. , Nov. 05, 2019 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics
NORCROSS, Ga. , Sept. 17, 2019 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, and Providence Cancer Institute announced today they have received notice of issuance of U.S.
NORCROSS, Ga. , Aug. 09, 2019 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the three months ended June 30, 2019 .
NORCROSS, Ga. , Aug. 05, 2019 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced it has submitted for assessment the Phase 3 protocol for using belapectin (GR-MD-02) for the treatment of compensated
NORCROSS, Ga. , May 28, 2019 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced its Rights Offering has closed. The Rights Offering resulted in the issuance of approximately 10.4 million shares of the
NORCROSS, Ga. , May 23, 2019 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported the Alternate Price (i.e., the final computed price) of the common stock and related warrant subscribed in its Rights
NORCROSS, Ga. , May 10, 2019 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today released this open letter to stockholders written by its Board Chair Richard E. Uihlein . The letter reads as follows: Dear Fellow
Subscription rights to purchase Galectin Therapeutics, Inc. common shares, with accompanying warrants, mailed to Holders of Record as of April 29. Rights expire at 5:00 PM Eastern on May 23, 2019 Portion of the Net Proceeds of Rights Offering to be used for Phase 3 clinical trial of belapectin,
NORCROSS, Ga. , April 15, 2019 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced that it has set key dates and pricing structure for its previously announced rights offering of approximately 14 million
NORCROSS, Ga. , April 02, 2019 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that Dr. Harold Shlevin , the Company’s President and Chief Executive Officer, will present at the H.C.
NORCROSS, Ga. , March 22, 2019 (GLOBE NEWSWIRE) -- Providence Cancer Institute and Galectin Therapeutics Inc. (NASDAQ: GALT) , the leading developer of therapeutics that target galectin proteins, announced today a presentation highlighting the improved response of T cells seen in combination
NORCROSS, Ga. , March 06, 2019 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today released this open letter to stockholders written by its Board Chair Richard E. Uihlein . The letter reads as follows: Dear
Richard E. Uihlein, Board Chair, expresses interest in investing $20.0 million in the Rights Offering NORCROSS, Ga. , March 06, 2019 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today filed a Registration
Planning for Phase 3 clinical trial (NASH-RX) nearing completion for GR-MD-02, the first drug to show positive results in a clinical trial in patients with compensated NASH cirrhosis NORCROSS, Ga. , March 06, 2019 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc.
NORCROSS, Ga. , Feb. 25, 2019 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that Dr. Harold H. Shlevin , the Company’s President and CEO, will present at Berenberg NASH Day at the Berenberg Offices
Board Chairman Richard Uihlein extends existing $10 million unsecured line of credit for two additional years NORCROSS, Ga. , Jan. 15, 2019 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced that its
NORCROSS, Ga. , Dec. 20, 2018 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced that its $10 million unsecured line of credit entered into on December 19, 2017 , has been extended by one year for both
NORCROSS, Ga. , Nov. 19, 2018 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that Dr. Harold H. Shlevin , the Company’s President and CEO, will present at the 2nd Annual Anti-Fibrotic Drug
NORCROSS, Ga. , Nov. 13, 2018 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT ), the leading developer of therapeutics that target galectin proteins, today reported financial results for its third fiscal quarter, which ended September 30, 2018 , and provided a business update.
NORCROSS, Ga. , Nov. 05, 2018 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that an abstract based on results obtained in Galectin Therapeutics’ NASH-CX Phase 2 Clinical Trial has been accepted for
NORCROSS, Ga. , Oct. 15, 2018 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that management will participate in the upcoming ROTH Capital Battle of the NASH Thrones Investor Conference being held
Combination immunotherapy of GR-MD-02 and KEYTRUDA for all cohorts reported shows an Objective Response Rate of 50% (seven of fourteen patients). The published response rate of KEYTRUDA alone is 33% in melanoma Providence Portland principal investigator, Dr.
NORCROSS, Ga. , Aug. 28, 2018 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that Dr. Harold H. Shlevin , the Company’s President and CEO, will present at the H.C.
NORCROSS, Ga. , Aug. 14, 2018 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results for its second fiscal quarter, which ended June 30, 2018 , and provided a business update.
NORCROSS, Ga. , June 27, 2018 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today announced that the Company has received notice of issuance of U.S. Patent Number 9,968,631 titled
Galectin Therapeutics is dedicated to developing novel therapies to improve the lives of patients with chronic liver disease and cancer. Galectin's lead drug (GR-MD-02) is a carbohydrate drug that inhibits the galectin-3 protein that is directly involved in multiple inflammatory, fibrotic, and
NORCROSS, Ga. , June 12, 2018 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that Harold H. Shlevin , Ph.D., currently the Company’s Chief Operating Officer (COO), has been appointed Chief Executive
NORCROSS, Ga. , June 04, 2018 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, announced today that the directors elected Richard E. Uihlein as Chairman of the Board of Directors. Additionally, Kevin D.
NORCROSS, Ga. , May 14, 2018 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, announced today it is proceeding with plans for a Phase 3 clinical trial program with its galectin-3 inhibitor GR-MD-02 in NASH cirrhosis,
NORCROSS, Ga. , May 11, 2018 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results for the three months ended March 31, 2018 , and provided a business update.
NORCROSS, Ga. , April 18, 2018 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that Peter G. Traber , M.D., the Company’s CEO and CMO, has been selected as an expert speaker and will participate in
NORCROSS, Ga. , April 16, 2018 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today provided highlights from a late-breaker oral presentation at The International Liver Congress™ 2018 , European Association for the
GR-MD-02 treatment in NASH cirrhosis patients without esophageal varices shows statistically significant and clinically meaningful effects NORCROSS, Ga. , April 04, 2018 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. ( NASDAQ:GALT ) , the leading developer of therapeutics that target galectin
NORCROSS, Ga. , April 02, 2018 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that Peter G. Traber , M.D., the Company’s CEO and CMO, will present at the H.C.
NORCROSS, Ga. , March 29, 2018 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results for the year ended December 31, 2017 . These results are included in the Company's Annual Report on Form
NORCROSS, Ga. , March 09, 2018 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that Peter G. Traber , M.D., the Company’s CEO and CMO, will participate in two upcoming international conferences in
NORCROSS, Ga. , March 08, 2018 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that Dr. Harold Shlevin , the Company’s Chief Operating Officer, will present at the 2 nd Annual H.C.
NORCROSS, Ga. , March 05, 2018 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced March 26, 2018 is the record date for the 2018 Annual Meeting of Stockholders to be held on May 22, 2018 in Atlanta, GA.
